You are here: Industry Insights > R&D

News List

Weekly Pharma News Review | PharmaSources.com (0926-0930) PharmaSources.com
October 08, 2022
The news reviewed this week is from September 26 to 30, covering a total of 26 pieces of information in 4 sections, i.e. drug review, R&D, business and policy.
Weekly Pharma News Review | PharmaSources.com (0919-0923) PharmaSources.com
September 26, 2022
The news reviewed this week is from September 19 to 23, covering a total of 25 pieces of information in 4 sections, i.e. drug review, R&D, and business and listing.
Weekly Pharma News Review | PharmaSources.com (0912-0916) PharmaSources.com
September 20, 2022
The news reviewed this week is from September 12 to 16, covering a total of 26 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Weekly Pharma News Review | PharmaSources.com (0905-0909) PharmaSources.com
September 14, 2022
The news review of this week is from September 5 to 9, covering a total of 25 pieces of information in 3 sections, i.e., drug review, R&D, and business.
Weekly Pharma News Review | PharmaSources.com (0829-0902) PharmaSources.com
September 06, 2022
This week, the second biological drug developed by SinoCellTech - ripertamab, a new anti-CD20 monoclonal antibody, was approved for marketing, which aroused the attention of the industry. The news review of this week is from August 29 to September 2.
Weekly Pharma News Review | PharmaSources.com (0822-0826) PharmaSources.com
August 29, 2022
The EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. The news review of this week is from August 22 to 26, covering a total of 20 pieces of information on drug review, R&D, business, and policy.
Weekly Pharma News Review | PharmaSources.com (0815-0819) PharmaSources.com
August 23, 2022
Alphamab Oncology’s JSKN003 injection became the first Chinese bispecific antibody ADC declared for clinical use. The news review of this week is from August 15 to 19, covering a total of 24 pieces of information on drug review, R&D, and business.
A Review of the Current Situation of COVID-19 R&D in China with Two More COVID-19 Vaccines Marketed PharmaSources/Yefenghong
May 31, 2021
On Feb. 25, the National Medical Products Administration of China (NMPA) conditionally approved the registration applications of two COVID-19 vaccines: Inactivated COVID-19 Vaccine (Vero Cell) of Sinopharm Wuhan Institute of Biological Products Co., Ltd.
Pharmaceutical News of the Week June 8th-12th | PharmaSources.com PharmaSources/Caicai
June 22, 2020
With the second week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 8-12.
Evolving World of Pharma: A framework for funding innovation Sarah Harding
April 09, 2020
Modern R&D models are being built on the integration of physical, chemical and computer sciences, and a commercial model that is increasingly played out within a framework of external funding for innovation. Under this model, new biotechs and other start-

Previous page 1 2 3 4 5 6 7 Next page